Purpose The rate of interval colorectal cancer (iCRC) is now accepted as a key performance indicator of organized colorectal cancer (CRC) screening programs. We aimed to examine the association between endoscopist volumes and the rate of iCRC among individuals with a positive fecal immunochemical test (FIT) within a nationwide population-based CRC screening program.
Materials and Methods Individuals aged ≥ 50 years who underwent colonoscopy after a positive FIT from January 1, 2019 until December 31, 2020 in the Korean National Cancer Screening Program (KNCSP) were enrolled. We converted the data into per-endoscopist screening results, calculated the iCRC rates per endoscopist, and compared them to the previous year’s annual volume that was divided into five groups (V1, 1-9; V2, 10-29; V3, 30-59; V4, 60-119; V5, ≥ 120).
Results A total of 10,412 endoscopists performed 216,907 colonoscopies. Overall, the average rate of iCRC per endoscopist was 8.46 per 1,000 examinations. Compared with the group with the highest volume (V5 group), the rate of iCRC was 2.21 times higher in the V1 group. Similar trends were observed in the other groups (V2: relative risks [RR], 2.15; 95% confidence interval [CI], 1.57 to 2.94; V3: RR, 1.56; 95% CI, 1.15 to 2.13; V4: RR, 1.18; 95% CI, 0.83 to 1.67).
Conclusion The findings emphasize that endoscopists with lower procedure volumes have higher risks of interval cancer being missed or undetected. To maximize the preventative impact of colonoscopy for CRC, this issue should be addressed by monitoring endoscopist volumes and variations in performances.
Semin Cho, Eunjeong Kang, Ji Eun Kim, U Kang, Hee Gyung Kang, Minsu Park, Kwangsoo Kim, Dong Ki Kim, Kwon Wook Joo, Yon Su Kim, Hyung-Jin Yoon, Hajeong Lee
Cancer Res Treat. 2021;53(4):1015-1023. Published online January 18, 2021
Purpose
Acute kidney injury (AKI) in cancer patients is associated with increased morbidity and mortality. The incidence of AKI in lung cancer seems to be relatively higher compared with other solid organ malignancies, although its impact on patient outcomes remains unclear.
Materials and Methods
The patients newly diagnosed with lung cancer from 2004 to 2013 were enrolled in this retrospective cohort study. The patients were categorized according to the presence and severity of AKI. We compared all-cause mortality and long-term renal outcome according to AKI stage.
Results
A total of 3,202 patients were included in the final analysis. AKI occurred in 1,783 (55.7%) patients during the follow-up period, with the majority having mild AKI stage 1 (75.8%). During the follow-up of 2.6±2.2 years, total 1,251 patients (53.7%) were died and 5-year survival rate was 46.9%. We found that both AKI development and severity were independent risk factors for all-cause mortality in lung cancer patients, even after adjustment for lung cancer-specific variables including the stage or pathological type. In addition, patients suffered from more severe AKI tend to encounter de novo chronic kidney disease development, worsening kidney function, and end-stage kidney disease progression.
Conclusion
In this study, more than half of the lung cancer patients experienced AKI during their diagnosis and treatment period. Moreover, AKI occurrence and more advanced AKI were associated with a higher mortality risk and adverse kidney outcomes.
Citations
Citations to this article as recorded by
Acute kidney injury associated with anti-PD-1 and anti-PD-L1 drugs: a meta-analysis of randomized clinical trials Isabela Gonçalves Lima, Isabele Benck Usiro Cabral da Silva, Vitória Carpentieri Pípolo, Vinicius Daher Alvares Delfino, Paulo Roberto Bignardi Immunopharmacology and Immunotoxicology.2024; 46(4): 470. CrossRef
Prevalence of kidney disease in patients with different types of cancer or hematological malignancies: a cross-sectional study Feng Wu, Shiyuan Wang, Jialing Zhang, Peixin Wang, Aihua Zhang International Urology and Nephrology.2024; 56(12): 3835. CrossRef
Protective effect of reduced glutathione on acute kidney injury in lung cancer patients treated with cisplatin: a retrospective cohort study Ying Huang, Yang Li, Xialian Xu, Jie Teng, Xiaoqiang Ding, Jiarui Xu Renal Failure.2024;[Epub] CrossRef
Association between renal dysfunction and outcomes of lung cancer: A systematic review and meta‑analysis Huijuan Qian, Si Li, Ziyun Hu Oncology Letters.2024;[Epub] CrossRef
Association and prediction of red blood cell distribution width to albumin ratio in all-cause mortality of acute kidney injury in critically ill patients Chen Gao, Longkai Peng Frontiers in Medicine.2023;[Epub] CrossRef
Point of care ultrasonography in onco-nephrology: A stride toward better physical examination Bhavna Bhasin-Chhabra, Abhilash Koratala World Journal of Nephrology.2023; 12(2): 29. CrossRef
Protocolo diagnóstico y tratamiento de la nefropatía en los pacientes con neoplasia sólida Rodríguez Doyágüez, M.P. Morán Magro, C.M. Durán López, P. Martínez Miguel Medicine - Programa de Formación Médica Continuada Acreditado.2023; 13(82): 4870. CrossRef
Sun Min Lim, Sang Hee Cho, In Gyu Hwang, Jae Woo Choi, Hyun Chang, Myung-Ju Ahn, Keon Uk Park, Ji-Won Kim, Yoon Ho Ko, Hee Kyung Ahn, Byoung Chul Cho, Byung-Ho Nam, Sang Hoon Chun, Ji Hyung Hong, Jung Hye Kwon, Jong Gwon Choi, Eun Joo Kang, Tak Yun, Keun-Wook Lee, Joo-Hang Kim, Jin Soo Kim, Hyun Woo Lee, Min Kyoung Kim, Dongmin Jung, Ji Eun Kim, Bhumsuk Keam, Hwan Jung Yun, Sangwoo Kim, Hye Ryun Kim
Cancer Res Treat. 2019;51(1):300-312. Published online May 9, 2018
Purpose
Head and neck squamous cell carcinoma (HNSCC) is a deadly disease in which precision medicine needs to be incorporated. We aimed to implement next-generation sequencing (NGS) in determining actionable targets to guide appropriate molecular targeted therapy in HNSCC patients.
Materials and Methods
Ninety-three tumors and matched blood samples underwent targeted sequencing of 244 genes using the Illumina HiSeq 2500 platform with an average depth of coverage of greater than 1,000×. Clinicopathological data from patients were obtained from 17 centers in Korea, and were analyzed in correlation with NGS data.
Results
Ninety-two of the 93 tumors were amenable to data analysis. TP53 was the most common mutation, occurring in 47 (51%) patients, followed by CDKN2A (n=23, 25%), CCND1 (n=22, 24%), and PIK3CA (n=19, 21%). The total mutational burden was similar between human papillomavirus (HPV)–negative vs. positive tumors, although TP53, CDKN2A and CCND1 gene alterations occurred more frequently in HPV-negative tumors. HPV-positive tumors were significantly associated with immune signature-related genes compared to HPV-negative tumors. Mutations of NOTCH1 (p=0.027), CDKN2A (p < 0.001), and TP53 (p=0.038) were significantly associated with poorer overall survival. FAT1 mutations were highly enriched in cisplatin responders, and potentially targetable alterations such as PIK3CA E545K and CDKN2A R58X were noted in 14 patients (15%).
Conclusion
We found several targetable genetic alterations, and our findings suggest that implementation of precision medicine in HNSCC is feasible. The predictive value of each targetable alteration should be assessed in a future umbrella trial using matched molecular targeted agents.
Citations
Citations to this article as recorded by
Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial Bhumsuk Keam, Min Hee Hong, Seong Hoon Shin, Seong Gu Heo, Ji Eun Kim, Hee Kyung Ahn, Yun-Gyoo Lee, Keon-Uk Park, Tak Yun, Keun-Wook Lee, Sung-Bae Kim, Sang-Cheol Lee, Min Kyoung Kim, Sang Hee Cho, So Yeon Oh, Sang-Gon Park, Shinwon Hwang, Byung-Ho Nam, S Journal of Clinical Oncology.2024; 42(5): 507. CrossRef
A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma: In-Depth Analysis of Nintedanib Arm from the KCSG HN 15-16 TRIUMPH Trial Kyoo Hyun Kim, Sun Min Lim, Hee Kyung Ahn, Yun-Gyoo Lee, Keun-Wook Lee, Myung-Ju Ahn, Bhumsuk Keam, Hye Ryun Kim, Hyun Woo Lee, Ho Jung An, Jin-Soo Kim Cancer Research and Treatment.2024; 56(1): 37. CrossRef
Extracellular vesicles as tools and targets in therapy for diseases Mudasir A. Kumar, Sadaf K. Baba, Hana Q. Sadida, Sara Al. Marzooqi, Jayakumar Jerobin, Faisal H. Altemani, Naseh Algehainy, Mohammad A. Alanazi, Abdul-Badi Abou-Samra, Rakesh Kumar, Ammira S. Al-Shabeeb Akil, Muzafar A. Macha, Rashid Mir, Ajaz A. Bhat Signal Transduction and Targeted Therapy.2024;[Epub] CrossRef
Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study Dong Hyun Kim, Seung Taek Lim, Hye Ryun Kim, Eun Joo Kang, Hee Kyung Ahn, Yun-Gyoo Lee, Der Sheng Sun, Jung Hye Kwon, Sang-Cheol Lee, Hyun Woo Lee, Min Kyoung Kim, Bhumsuk Keam, Keon-Uk Park, Seong-Hoon Shin, Hwan Jung Yun Oral Oncology.2024; 151: 106739. CrossRef
Characterization of macrophages in head and neck squamous cell carcinoma and development of MRG-based risk signature Lei Liu, Qiang Liu Scientific Reports.2024;[Epub] CrossRef
The Next Chapter in Cancer Diagnostics: Advances in HPV-Positive Head and Neck Cancer Antea Krsek, Lara Baticic, Tamara Braut, Vlatka Sotosek Biomolecules.2024; 14(8): 925. CrossRef
Biomarkers in head and neck squamous cell carcinoma: unraveling the path to precision immunotherapy Kamal S. Saini, Sasikala Somara, Heidi C. Ko, Purva Thatai, Angela Quintana, Zachary D. Wallen, Michelle F. Green, Ravi Mehrotra, Sandra McGuigan, Lingjuan Pang, Soma Das, Kavita Yadav, Dobrica Neric, Luca Cantini, Chinmayee Joshi, Kazuya Iwamoto, Sudha D Frontiers in Oncology.2024;[Epub] CrossRef
Massive parallel sequencing of head and neck conventional squamous cell carcinomas: A comprehensive review Alfons Nadal, Antonio Cardesa, Abbas Agaimy, Alhadi Almangush, Alessandro Franchi, Henrik Hellquist, Ilmo Leivo, Nina Zidar, Alfio Ferlito Virchows Archiv.2024; 485(6): 965. CrossRef
FAT1 expression in T-cell acute lymphoblastic leukemia (T-ALL) modulates proliferation and WNT signaling Sven Liebig, Martin Neumann, Patricia Silva, Jutta Ortiz-Tanchez, Veronika Schulze, Konstandina Isaakidis, Cornelia Schlee, Michael P. Schroeder, Thomas Beder, Luc G. T. Morris, Timothy A. Chan, Lorenz Bastian, Thomas Burmeister, Stefan Schwartz, Nicola G Scientific Reports.2023;[Epub] CrossRef
Short-term immune-checkpoint inhibition partially rescues perturbed bone marrow hematopoiesis in mismatch-repair deficient tumors Paula Krone, Annabell Wolff, Julia Teichmann, Johanna Maennicke, Julia Henne, Leonie Engster, Inken Salewski, Wendy Bergmann, Christian Junghanss, Claudia Maletzki OncoImmunology.2023;[Epub] CrossRef
Genetic Mutations Associated with Inflammatory Response Caused by HPV Integration in Oropharyngeal Squamous Cell Carcinoma Mai Atique, Isis Muniz, Fatemeh Farshadi, Michael Hier, Alex Mlynarek, Marco Macarella, Mariana Maschietto, Belinda Nicolau, Moulay A. Alaoui-Jamali, Sabrina Daniela da Silva Biomedicines.2023; 12(1): 24. CrossRef
New Treatment Development for Larynx Preservation Susumu Okano Koutou (THE LARYNX JAPAN).2023; 35(2): 98. CrossRef
Current Trends in Precision Medicine and Next-Generation Sequencing in Head and Neck Cancer Roberto N. Solis, Dustin A. Silverman, Andrew C. Birkeland Current Treatment Options in Oncology.2022; 23(2): 254. CrossRef
EGFR Mutation and 11q13 Amplification Are Potential Predictive Biomarkers for Immunotherapy in Head and Neck Squamous Cell Carcinoma Shengjin Dou, Lin Zhang, Chong Wang, Yanli Yao, Wen Jiang, Lulu Ye, Jiang Li, Sicheng Wu, Debin Sun, Xiaoli Gong, Rongrong Li, Guopei Zhu Frontiers in Immunology.2022;[Epub] CrossRef
Diagnostics of HNSCC Patients: An Analysis of Cell Lines and Patient-Derived Xenograft Models for Personalized Therapeutical Medicine Ramona Gabriela Ursu, Ionut Luchian, Costin Damian, Elena Porumb-Andrese, Nicolae Ghetu, Roxana Gabriela Cobzaru, Catalina Lunca, Carmen Ripa, Diana Costin, Igor Jelihovschi, Florin Dumitru Petrariu, Luminita Smaranda Iancu Diagnostics.2022; 12(5): 1071. CrossRef
Unraveling most abundant mutational signatures in head and neck cancer Michaela Plath, Johanna Gass, Mario Hlevnjak, Qiaoli Li, Bohai Feng, Xavier Pastor Hostench, Matthias Bieg, Lea Schroeder, Dana Holzinger, Marc Zapatka, Kolja Freier, Wilko Weichert, Jochen Hess, Karim Zaoui International Journal of Cancer.2021; 148(1): 115. CrossRef
Worldwide prevalence of PI3K-AKT-mTOR pathway mutations in head and neck cancer: A systematic review and meta-analysis Adriana Castelo de Moura, Daniele Xavier Assad, Juliana Amorim dos Santos, Isabela Porto de Toledo, Gustavo Barcelos Barra, Rogerio Moraes Castilho, Cristiane Helena Squarize, Eliete Neves Silva Guerra Critical Reviews in Oncology/Hematology.2021; 160: 103284. CrossRef
Immuno-Oncological Biomarkers for Squamous Cell Cancer of the Head and Neck: Current State of the Art and Future Perspectives Stijn J. De Keukeleire, Tijl Vermassen, Elien Hilgert, David Creytens, Liesbeth Ferdinande, Sylvie Rottey Cancers.2021; 13(7): 1714. CrossRef
Comprehensive Analysis of Mutation-Based and Expressed Genes-Based Pathways in Head and Neck Squamous Cell Carcinoma Bhumsuk Keam, Jin-Young Park, Jin-Pyo Kim, Gun-Do Kim, Yun-Suk Yu, Sang-Hee Cho, Sangwoo Kim, Hee-Kyung Ahn, Sang-Hoon Chun, Jung-Hye Kwon, Tak Yun, Ji-Won Kim, Ji-Eun Kim, Myung-Ju Ahn, Joo-Hang Kim, Hwan-Jung Yun Processes.2021; 9(5): 792. CrossRef
Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma Teresa Magnes, Sandro Wagner, Dominik Kiem, Lukas Weiss, Gabriel Rinnerthaler, Richard Greil, Thomas Melchardt International Journal of Molecular Sciences.2021; 22(9): 4981. CrossRef
A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma Ji Hyun Lee, Seong Gu Heo, Beung‐Chul Ahn, Min Hee Hong, Byoung Chul Cho, Sun Min Lim, Hye Ryun Kim Cancer Medicine.2021; 10(20): 7012. CrossRef
Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma Nan Jin, Bhumsuk Keam, Janice Cho, Michelle J. Lee, Hye Ryun Kim, Hayarpi Torosyan, Natalia Jura, Patrick K.S. Ng, Gordon B. Mills, Hua Li, Yan Zeng, Zohar Barbash, Gabi Tarcic, Hyunseok Kang, Julie E. Bauman, Mi-Ok Kim, Nathan K. VanLandingham, Danielle Journal of Clinical Investigation.2021;[Epub] CrossRef
Understanding the Pattern of Oropharyngeal Cancers from North-East Romanian Patients Ramona Ursu, Simona Giusca, Irene Spiridon, Bianca Manole, Mihai Danciu, Victor Costan, Dragos Palade, Nicolae Ghetu, Paula Toader, Mădălina Vlad, Costin Damian, Elena Porumb-Andrese, Ionut Luchian, Luminița Iancu Applied Sciences.2021; 11(24): 12079. CrossRef
Immunologic and immunogenomic aspects of tumor progression Andrea Ladányi, József Tímár Seminars in Cancer Biology.2020; 60: 249. CrossRef
Prospective assessment of the clinical benefit of a tailored cancer gene set built on a next-generation sequencing platform in patients with recurrent or metastatic head and neck cancer Thomas C. Westbrook, Ian S. Hagemann, Jessica Ley, Kevin Chen, Kevin Palka, Jingxia Liu, Ling Chen, Peter Oppelt, Douglas Adkins Medical Oncology.2020;[Epub] CrossRef
Biological Determinants of Chemo-Radiotherapy Response in HPV-Negative Head and Neck Cancer: A Multicentric External Validation Martijn van der Heijden, Paul B. M. Essers, Monique C. de Jong, Reinout H. de Roest, Sebastian Sanduleanu, Caroline V. M. Verhagen, Olga Hamming-Vrieze, Frank Hoebers, Philippe Lambin, Harry Bartelink, C. René Leemans, Marcel Verheij, Ruud H. Brakenhoff, Frontiers in Oncology.2020;[Epub] CrossRef
Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response Min Hwan Kim, Jae-Hwan Kim, Ji Min Lee, Jae Woo Choi, Dongmin Jung, Hojin Cho, Hyundeok Kang, Min Hee Hong, Su Jin Heo, Se Heon Kim, Eun Chang Choi, Da Hee Kim, Young Min Park, Sangwoo Kim, Sun Och Yoon, Yoon Woo Koh, Byoung Chul Cho, Hye Ryun Kim British Journal of Cancer.2020; 122(11): 1649. CrossRef
Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer Han Na Kang, Jae-Hwan Kim, A-Young Park, Jae Woo Choi, Sun Min Lim, Jinna Kim, Eun Joo Shin, Min Hee Hong, Kyoung-Ho Pyo, Mi Ran Yun, Dong Hwi Kim, Hanna Lee, Sun Och Yoon, Da Hee Kim, Young Min Park, Hyung Kwon Byeon, Inkyung Jung, Soonmyung Paik, Yoon W BMC Cancer.2020;[Epub] CrossRef
Impact of genetic variants in clinical outcome of a cohort of patients with oropharyngeal squamous cell carcinoma Ana Carolina de Carvalho, Sandra Perdomo, Wellington dos Santos, Gabriela Carvalho Fernandes, Lais Machado de Jesus, Raiany Santos Carvalho, Cristovam Scapulatempo-Neto, Gisele Caravina de Almeida, Bruna Pereira Sorroche, Lidia Maria Rebolho Batista Arant Scientific Reports.2020;[Epub] CrossRef
Prognostic Value of CD200R1 mRNA Expression in Head and Neck Squamous Cell Carcinoma Hyun Chang, Yun-Gyoo Lee, Yoon Ho Ko, Jang Ho Cho, Jong-Kwon Choi, Keon Uk Park, Eun Joo Kang, Keun-Wook Lee, Sun Min Lim, Jin-Soo Kim, Hyun Woo Lee, Min Kyoung Kim, In Gyu Hwang, Sangwoo Kim, Byung-Ho Nam, Hye Ryun Kim Cancers.2020; 12(7): 1777. CrossRef
Mouse–human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck Hye Ryun Kim, Han Na Kang, Mi Ran Yun, Kwon Young Ju, Jae Woo Choi, Dong Min Jung, Kyoung Ho Pyo, Min Hee Hong, Myoung-Ju Ahn, Jong-Mu Sun, Han Sang Kim, Jinna Kim, Jinseon Yoo, Kyu Ryung Kim, Yoon Woo Koh, Se Heon Kim, Eun Chang Choi, Sun Ock Yoon, Hyo S British Journal of Cancer.2020; 123(12): 1720. CrossRef
Mutationssignaturen beim Kopf- und Hals-Tumor M. Plath, J. Hess, K. Zaoui HNO.2020; 68(12): 922. CrossRef
BAMixChecker: an automated checkup tool for matched sample pairs in NGS cohort Hein Chun, Sangwoo Kim, Inanc Birol Bioinformatics.2019; 35(22): 4806. CrossRef
Diagnostic Tumor Markers in Head and Neck Squamous Cell Carcinoma (HNSCC) in the Clinical Setting Panagiota Economopoulou, Remco de Bree, Ioannis Kotsantis, Amanda Psyrri Frontiers in Oncology.2019;[Epub] CrossRef
A Review of HPV-Related Head and Neck Cancer Kazuhiro Kobayashi, Kenji Hisamatsu, Natsuko Suzui, Akira Hara, Hiroyuki Tomita, Tatsuhiko Miyazaki Journal of Clinical Medicine.2018; 7(9): 241. CrossRef
Kyung Jin Eoh, Ji Eun Kim, Hyung Seok Park, Seung-Tae Lee, Ji Soo Park, Jung Woo Han, Jung-Yun Lee, Sunghoon Kim, Sang Wun Kim, Jae Hoon Kim, Young Tae Kim, Eun Ji Nam
Cancer Res Treat. 2018;50(3):917-925. Published online September 27, 2017
Purpose
Next-generation sequencing (NGS) allows simultaneous sequencing of multiple cancer susceptibility genes and may represent a more efficient and less expensive approach than sequential testing. We assessed the frequency of germline mutations in individuals with epithelial ovarian cancer (EOC), using multi-gene panels and NGS.
Materials and Methods
Patients with EOC (n=117) with/without a family history of breast or ovarian cancer were recruited consecutively, from March 2016 toDecember 2016.GermlineDNAwas sequenced using 35-gene NGS panel, in order to identify mutations. Upon the detection of a genetic alteration using the panel, results were cross-validated using direct sequencing.
Results
Thirty-eight patients (32.5%) had 39 pathogenic or likely pathogenic mutations in eight genes, including BRCA1 (n=21), BRCA2 (n=10), BRIP1 (n=1), CHEK2 (n=2), MSH2 (n=1), POLE (n=1), RAD51C (n=2), and RAD51D (n=2). Among 64 patients with a family history of cancer, 27 (42.2%) had 27 pathogenic or likely pathogenic mutations, and six (9.3%) had mutations in genes other than BRCA1/2, such as CHECK2, MSH2, POLE, and RAD51C. Fifty-five patients (47.0%) were identified to carry only variants of uncertain significance.
Conclusion
Using the multi-gene panel test, we found that, of all patients included in our study, 32.5% had germline cancer-predisposing mutations. NGS was confirmed to substantially improve the detection rates of a wide spectrum of mutations in EOC patients compared with those obtained with the BRCA1/2 testing alone.
Citations
Citations to this article as recorded by
Germline mutations of 4567 patients with hereditary breast-ovarian cancer spectrum in Thailand Chalermkiat Kansuttiviwat, Pongtawat Lertwilaiwittaya, Ekkapong Roothumnong, Panee Nakthong, Peerawat Dungort, Chutima Meesamarnpong, Warisara Tansa-Nga, Khontawan Pongsuktavorn, Supakit Wiboonthanasarn, Warunya Tititumjariya, Nannipa Phuphuripan, Chittap npj Genomic Medicine.2024;[Epub] CrossRef
Germline Mutational Landscape and Novel Targetable RAD51D Variant in Chinese Patients With Ovarian Cancer Zheng Feng, Siyu Chen, Na An, Zhihui Xiu, Xingzhu Ju, Xiaojun Chen, Rui Bi, Jie Wang, Shida Zhu, Xiaohua Wu, Hao Wen JCO Global Oncology.2024;[Epub] CrossRef
Germline Genetic Testing for Hereditary Breast and Ovarian Cancer: Current Concepts in Risk Evaluation Siddhartha Yadav, Fergus J. Couch, Susan M. Domchek Cold Spring Harbor Perspectives in Medicine.2024; 14(8): a041318. CrossRef
Germline RAD51C and RAD51D Mutations in High-Risk Chinese Breast and/or Ovarian Cancer Patients and Families Ava Kwong, Cecilia Yuen Sze Ho, Chun Hang Au, Sze Keong Tey, Edmond Shiu Kwan Ma Journal of Personalized Medicine.2024; 14(8): 866. CrossRef
Clinical Significance of PALB2 Pathogenic Germline Variant Min-Chae Kang, R.N., Jong Eun Park, Mi-Ae Jang, Dongju Won, Boyoung Park, Seeyoun Lee, Dong Ock Lee, Kum Hei Ryu, Yoon-Jung Chang, Sun-Young Kong Laboratory Medicine Online.2024; 14(4): 311. CrossRef
Molecular profiling reveals novel therapeutic targets and clonal evolution in ovarian clear cell carcinoma Angel Chao, Chen-Yang Huang, Willie Yu, Chiao-Yun Lin, Hao Lin, An-Shine Chao, Cheng-Tao Lin, Hung-Hsueh Chou, Kuang-Gen Huang, Huei-Jean Huang, Ting-Chang Chang, Steven G. Rozen, Ren-Chin Wu, Chyong-Huey Lai BMC Cancer.2024;[Epub] CrossRef
Next-generation sequencing uncovers crucial mutated genes and potential therapeutic targets in ovarian cancer patients Tianjiao Zhao American Journal of Translational Research.2024; 16(10): 5990. CrossRef
The expression and mutation of BRCA1/2 genes in ovarian cancer: a global systematic study Dinh-Toi Chu, Mai Vu Ngoc Suong, Hue Vu Thi, Thuy-Duong Vu, Manh-Hung Nguyen, Vijai Singh Expert Review of Molecular Diagnostics.2023; 23(1): 53. CrossRef
Using species richness calculations to model the global profile of unsampled pathogenic variants: Examples from BRCA1 and BRCA2 Nandana D. Rao, Brian H. Shirts, Alvaro Galli PLOS ONE.2023; 18(2): e0278010. CrossRef
Risk-Reducing Breast and Gynecological Surgery for BRCA Mutation Carriers: A Narrative Review Serena Bertozzi, Ambrogio Londero, Anjeza Xholli, Guglielmo Azioni, Roberta Di Vora, Michele Paudice, Ines Bucimazza, Carla Cedolini, Angelo Cagnacci Journal of Clinical Medicine.2023; 12(4): 1422. CrossRef
Deregulated Metabolic Pathways in Ovarian Cancer: Cause and Consequence Roopak Murali, Vaishnavi Balasubramaniam, Satish Srinivas, Sandhya Sundaram, Ganesh Venkatraman, Sudha Warrier, Arun Dharmarajan, Rajesh Kumar Gandhirajan Metabolites.2023; 13(4): 560. CrossRef
Factors predictingBRCA1/2pathogenic variants in patients with ovarian cancer: a systematic review with meta-analysis Giovanni Innella, Lea Godino, Giulia Erini, Antonio De Leo, Donatella Santini, Anna Myriam Perrone, Pierandrea De Iaco, Claudio Zamagni, Daniela Turchetti Journal of Clinical Pathology.2023; 76(8): 510. CrossRef
Partner and localizer of BRCA2 (PALB2) pathogenic variants and ovarian cancer: A systematic review and meta-analysis. Priyanka Narayan, Muhammad Danyal Ahsan, Emily M. Webster, Luiza Perez, Sarah R. Levi, Benedict Harvey, Isabel Wolfe, Shanice Beaumont, Jesse T. Brewer, Drew Siegel, Charlene Thomas, Paul Christos, Andy Hickner, Eloise Chapman-Davis, Evelyn Cantillo, Kevi Gynecologic Oncology.2023; 177: 72. CrossRef
Early-Onset Ovarian Cancer <30 Years: What Do We Know about Its Genetic Predisposition? Klara Horackova, Marketa Janatova, Petra Kleiblova, Zdenek Kleibl, Jana Soukupova International Journal of Molecular Sciences.2023; 24(23): 17020. CrossRef
Effect of risk-reducing salpingo-oophorectomy on sex steroid hormone serum levels among postmenopausal women: an NRG Oncology/Gynecologic Oncology Group study Phuong L. Mai, Austin Miller, Amanda Black, Roni T. Falk, John F. Boggess, Katherine Tucker, Ashley R. Stuckey, Gustavo C. Rodriguez, Cheung Wong, Thomas T. Amatruda, Kelly J. Wilkinson, Susan C. Modesitt, S. Diane Yamada, Kristin L. Bixel, Gretchen E. Gl American Journal of Obstetrics and Gynecology.2022; 227(1): 61.e1. CrossRef
Hereditary gynecologic tumors and precision cancer medicine Chikako Ogawa, Akira Hirasawa, Naoyuki Ida, Keiichiro Nakamura, Hisashi Masuyama Journal of Obstetrics and Gynaecology Research.2022; 48(5): 1076. CrossRef
Discovery of BRCA1/BRCA2 founder variants by haplotype analysis Won Kyung Kwon, Hyeok-Jae Jang, Jeong Eon Lee, Yeon Hee Park, Jai Min Ryu, Jonghan Yu, Ja-Hyun Jang, Jong-Won Kim Cancer Genetics.2022; 266-267: 19. CrossRef
Epithelial Ovarian Cancer: Providing Evidence of Predisposition Genes Sidrah Shah, Alison Cheung, Mikolaj Kutka, Matin Sheriff, Stergios Boussios International Journal of Environmental Research and Public Health.2022; 19(13): 8113. CrossRef
Germline multigene panel testing revealed a BRCA2 pathogenic variant in a patient with suspected Lynch syndrome Tomoko Yoshihama, Akira Hirasawa, Kokichi Sugano, Teruhiko Yoshida, Mineko Ushiama, Arisa Ueki, Tomoko Akahane, Yoshiko Nanki, Kensuke Sakai, Takeshi Makabe, Wataru Yamagami, Nobuyuki Susumu, Kaori Kameyama, Kenjiro Kosaki, Daisuke Aoki International Cancer Conference Journal.2021; 10(1): 6. CrossRef
Prevalence of cancer susceptibility variants in patients with multiple Lynch syndrome related cancers Yoon Young Choi, Su-Jin Shin, Jae Eun Lee, Lisa Madlensky, Seung-Tae Lee, Ji Soo Park, Jeong-Hyeon Jo, Hyunki Kim, Daniela Nachmanson, Xiaojun Xu, Sung Hoon Noh, Jae-Ho Cheong, Olivier Harismendy Scientific Reports.2021;[Epub] CrossRef
Retroperitoneal leiomyosarcoma in a female patient with a germline splicing variant RAD51D c.904-2A > T: a case report Mashu Futagawa, Hideki Yamamoto, Mariko Kochi, Yusaku Urakawa, Reimi Sogawa, Fumino Kato, Mika Okazawa-Sakai, Daisuke Ennishi, Katsunori Shinozaki, Hirofumi Inoue, Hiroyuki Yanai, Akira Hirasawa Hereditary Cancer in Clinical Practice.2021;[Epub] CrossRef
A dominant RAD51C pathogenic splicing variant predisposes to breast and ovarian cancer in the Newfoundland population due to founder effect Lesa M. Dawson, Kerri N. Smith, Salem Werdyani, Robyn Ndikumana, Cindy Penney, Louisa L. Wiede, Kendra L. Smith, Justin A. Pater, Andrée MacMillan, Jane Green, Sheila Drover, Terry‐Lynn Young, Darren D. O’Rielly Molecular Genetics & Genomic Medicine.2020;[Epub] CrossRef
Germline and Somatic BRCA1/2 Mutations in 172 Chinese Women With Epithelial Ovarian Cancer Yan You, Lei Li, Junliang Lu, Huanwen Wu, Jing Wang, Jie Gao, Ming Wu, Zhiyong Liang Frontiers in Oncology.2020;[Epub] CrossRef
BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases Malwina Suszynska, Magdalena Ratajska, Piotr Kozlowski Journal of Ovarian Research.2020;[Epub] CrossRef
Summary of BARD1 Mutations and Precise Estimation of Breast and Ovarian Cancer Risks Associated with the Mutations Malwina Suszynska, Piotr Kozlowski Genes.2020; 11(7): 798. CrossRef
Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer Jin‐Sun Ryu, Hye‐Young Lee, Eun Hae Cho, Kyong‐Ah Yoon, Min‐Kyeong Kim, Jungnam Joo, Eun‐Sook Lee, Han‐Sung Kang, Seeyoun Lee, Dong Ock Lee, Myong Cheol Lim, Sun‐Young Kong Cancer Science.2020; 111(10): 3912. CrossRef
RAD51C and RAD51D in the hereditary breast and ovarian cancer syndrome Ana Isabel Sánchez Bermúdez, M.ª Desamparados Sarabia Meseguer, Verónica Guardiola Castillo, Francisco Ruiz Espejo, José Antonio Noguera Velasco Revista de Medicina de Laboratorio.2020;[Epub] CrossRef
Diagnostic yield and clinical utility of a comprehensive gene panel for hereditary tumor syndromes Jonas Henn, Isabel Spier, Ronja S. Adam, Stefanie Holzapfel, Siegfried Uhlhaas, Katrin Kayser, Guido Plotz, Sophia Peters, Stefan Aretz Hereditary Cancer in Clinical Practice.2019;[Epub] CrossRef
Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes — Providing evidence of cancer predisposition genes Malwina Suszynska, Katarzyna Klonowska, Anna J. Jasinska, Piotr Kozlowski Gynecologic Oncology.2019; 153(2): 452. CrossRef
Targeted sequencing of a specific gene panel detects a high frequency of ARID1A and PIK3CA mutations in ovarian clear cell carcinoma Yu-Fa Su, Eing-Mei Tsai, Chih-Chieh Chen, Chun-Chieh Wu, Tze-Kiong Er Clinica Chimica Acta.2019; 494: 1. CrossRef
Hereditary ovarian cancers: state of the art Angela Toss, Eleonora Molinaro, Margaret Sammarini, Maria C. Del Savio, Laura Cortesi, Fabio Facchinetti, Giovanni Grandi Minerva Medica.2019;[Epub] CrossRef
BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study Claudia Marchetti, Rossella De Leo, Angela Musella, Marco D’Indinosante, Ettore Capoluongo, Angelo Minucci, Pierluigi Benedetti Panici, Giovanni Scambia, Anna Fagotti Annals of Surgical Oncology.2018; 25(12): 3701. CrossRef
Spectrum and Prevalence of Pathogenic Variants in Ovarian Cancer Susceptibility Genes in a Group of 333 Patients Magdalena Koczkowska, Natalia Krawczynska, Maciej Stukan, Alina Kuzniacka, Izabela Brozek, Marcin Sniadecki, Jaroslaw Debniak, Dariusz Wydra, Wojciech Biernat, Piotr Kozlowski, Janusz Limon, Bartosz Wasag, Magdalena Ratajska Cancers.2018; 10(11): 442. CrossRef
Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap Jeanna M McCuaig, Tracy L Stockley, Patricia Shaw, Michael Fung-Kee-Fung, Alon D Altman, James Bentley, Marcus Q Bernardini, Beatrice Cormier, Hal Hirte, Katharina Kieser, Andree MacMillan, Wendy S Meschino, Karen Panabaker, Renee Perrier, Diane Provenche Journal of Medical Genetics.2018; 55(9): 571. CrossRef
Erdheim-Chester disease is a rare non-Langerhans–cell histiocytosis with bone and organ involvement. A 76-year-old man presented with low back pain and a history of visits for exertional dyspnea. We diagnosed him with anemia of chronic disease, cytopenia related to chronic illness, chronic renal failure due to hypertension, and hypothyroidism. However, we could not determine a definite cause or explanation for the cytopenia. Multiple osteosclerotic axial skeleton lesions and axillary lymph node enlargement were detected by computed tomography. Bone marrow biopsy revealed histiocytic infiltration, which was CD68-positive and CD1a-negative. This report describes an unusual presentation of Erdheim-Chester disease involving the bone marrow, axial skeleton, and lymph nodes.
Citations
Citations to this article as recorded by
Erdheim Chester Disease Mimicking Lymphoma: A Case Report Philipp Moritz Wunschel, Wolfgang Voss, Marc Keberle RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren.2022; 194(03): 310. CrossRef
Myelopathy Secondary to Isolated Thoracic Spine Involvement Mimicking Metastasis in Erdheim–Chester Disease Rajesh Rajavelu, Ajoy P. Shetty, Rishi M. Kanna, S Rajasekaran Indian Spine Journal.2021; 4(1): 133. CrossRef
Diagnosing a Patient with Erdheim-Chester Disease during the COVID-19 Pandemic Georgia Kaiafa, Dimitrios Pilalas, Triantafyllia Koletsa, Stylianos Daios, Georgios Arsos, Adam Hatzidakis, Adonis Protopapas, Kostas Stamatopoulos, Christos Savopoulos Medicina.2021; 57(10): 1001. CrossRef
Case of Erdheim–Chester presenting with xanthelasma-like eruption and osteolytic bone lesions: A case report Evelyn Alarcon Chinchilla, Marie-Pascale Gourde, Karine Turcotte, Steve Mathieu, Mohamed Amin-Hashem SAGE Open Medical Case Reports.2019;[Epub] CrossRef
Erdheim-Chester Disease Involving Lymph Nodes and Liver Clinically Mimicking Lymphoma: A Case Report Yeoun Eun Sung, Yoon Seo Lee, Jieun Lee, Kyo Young Lee Journal of Pathology and Translational Medicine.2018; 52(3): 183. CrossRef
Resolved heart tamponade and controlled exophthalmos, facial pain and diabetes insipidus due to Erdheim-Chester disease Jaume Monmany, Esther Granell, Laura López, Pere Domingo BMJ Case Reports.2018; : bcr-2018-225224. CrossRef
18F-FDG PET/CT in Erdheim–Chester Disease: Imaging Findings and Potential BRAF Mutation Biomarker Jason R. Young, Geoffrey B. Johnson, Robert C. Murphy, Ronald S. Go, Stephen M. Broski Journal of Nuclear Medicine.2018; 59(5): 774. CrossRef
Erdheim-Chester Disease with Emperipolesis: A Unique Case Involving the Heart Pengcheng Zhu, Naping Li, Lu Yu, Mariajose Navia Miranda, Guoping Wang, Yaqi Duan Cancer Research and Treatment.2017; 49(2): 553. CrossRef